See more : DOF ASA (DOF.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Estrella Immunopharma, Inc. (ESLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Estrella Immunopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TH International Limited (THCH) Income Statement Analysis – Financial Results
- Dollar Industries Limited (DOLLAR.NS) Income Statement Analysis – Financial Results
- Better Life Commercial Chain Share Co.,Ltd (002251.SZ) Income Statement Analysis – Financial Results
- MotorK plc (MTRK.AS) Income Statement Analysis – Financial Results
- QB Net Holdings Co.,Ltd. (6571.T) Income Statement Analysis – Financial Results
Estrella Immunopharma, Inc. (ESLA)
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.11M | 0.00 | 1.39M | 457.23K |
| General & Administrative | 3.20M | 0.00 | 296.25K | 276.46K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.20M | 1.37M | 296.25K | 276.46K |
| Other Expenses | 0.00 | -201.31K | -70.15K | 0.00 |
| Operating Expenses | 7.31M | 1.57M | 1.69M | 733.69K |
| Cost & Expenses | 7.31M | 1.57M | 1.69M | 733.69K |
| Interest Income | 0.00 | 654.07K | 1.43K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 228.49K | 236.56K | 206.30K |
| EBITDA | -7.31M | -915.46K | -247.72K | -733.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.31M | -1.57M | -1.69M | -733.69K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 654.07K | 1.44M | 0.00 |
| Income Before Tax | -7.31M | -915.46K | -1.69M | -733.69K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.63K | 80.65K | -235.14K | -206.30K |
| Net Income | -7.31M | -996.10K | -1.69M | -733.69K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.21 | -0.17 | -0.29 | -0.02 |
| EPS Diluted | -0.21 | -0.17 | -0.29 | -0.02 |
| Weighted Avg Shares Out | 35.20M | 5.76M | 5.85M | 35.20M |
| Weighted Avg Shares Out (Dil) | 35.20M | 5.76M | 5.85M | 35.20M |
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
Source: https://incomestatements.info
Category: Stock Reports